Author:
Aderemi Adenuga Babafunso
Abstract
Growing burden of communicable and non-communicable diseases in sub-Saharan Africa has necessitated the need for increased medicine use among the African population. Owing to the limited manufacturing capacity of medicines in the sub-continent, it became imperative for governments and Central Medical Stores to source medicines from countries such as India, Bangladesh and China. Such procurements were due to the affordability of generic products manufactured by manufacturers in these countries compared to innovator s, which might come at exorbitant prices and costs that might be prohibitive for most developing countries such as the ones in sub-Saharan Africa. Ascertaining the quality and efficacy of these products are always reliant on the judgment of national regulatory authorities (NRA), which might be ill equipped in most instances; human capacity both in knowledge and number are some of the banes of such NRAs. Aforesaid, pharmacovigilance does not take the front seat in most discussions rather the burden of diseases, thus the emphasis on medicines availability. Different researchers have highlighted the link between medicines/drugs availability and the need for pharmacovigilance among healthcare workers, policy makers and patients. Such approach will tend to limit the procurement of medicines that are substandard, falsified or fake, with the aim of protecting public health.
Reference18 articles.
1. World Health Organization. The Importance of Pharmacovigilance-Safety Monitoring of Medicinal Products. Geneva, Switzerland: WHO; 2002
2. Hazell L, Shakir SA. Under-reporting of adverse drug reactions : A systematic review. Drug Safety. 2006;29(5):385-396. DOI: 10.2165/00002018-200629050-00003
3. Barry A, Olsson S, Minzi O, et al. Comparative assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania. Drug Safety. 2020;43:339-350. DOI: 10.1007/s40264-019-00898-z
4. AHRQ. Improving Data Collection across the Health Care System. Rockville, MD: Agency for Healthcare Research and Quality; 2018. Available from: https://www.ahrq.gov/research/findings/final-reports/iomracereport/reldata5.html
5. Adenuga BA, Olafusi OO, Anaba A. Conceptual framework for effective stakeholder engagement for pharmacovigilance in a resource limited setting. Exploratory Research in Clinical and Social Pharmacy. 2021;1. DOI: 10.1016/j.rcsop.2021.100002
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献